BlueHaven Therapeutics

Executive Summary

BlueHaven Therapeutics (operating as Blue Wave Therapeutics) is a preclinical-stage biopharmaceutical company based in Munich, Germany, focused on developing targeted radionuclide therapies for solid tumors. Founded in 2020, the company leverages its proprietary radioactive biopolymer platform, which utilizes alginate nanoparticles to deliver radionuclide payloads directly to tumor cells while minimizing damage to healthy tissues. This approach aims to improve the therapeutic index of radionuclide therapy, addressing a key challenge in oncology. The company is private and has not disclosed total funding or valuation, indicating an early development phase. BlueHaven is positioned in the competitive radiopharmaceuticals space, which has seen growing interest from major pharma and investors.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead candidate nomination and IND-enabling studies50% success
• Q2 2027Initiation of first-in-human clinical trial for lead program30% success
• TBDPotential partnership or licensing deal for platform technology20% success